Endogenously elevated bilirubin modulates kidney function and protects from circulating oxidative stress in a rat model of adenine-induced kidney failure

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Boon, Ai Ching ^a   Lam, Alfred K ^b,c   Gopalan, Vinod ^b   Benzie, Iris F ^d   Briskey, David ^e   Coombes, Jeff S ^e   Fassett, Robert G ^e   Bulmer, Andrew C ^a  

^a GRIFFITH UNIVERSITY   (Australia)

^b GRIFFITH UNIVERSITY   (Australia)

^c GOLD COAST UNIVERSITY HOSPITAL   (Australia)

^d HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

^e UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; BILIRUBIN;

ANIMAL; BLOOD; GUNN RAT; KIDNEY FUNCTION TEST; METABOLISM; OXIDATIVE STRESS; RAT; RENAL INSUFFICIENCY; WISTAR RAT;

ADENINE; ANIMALS; BILIRUBIN; KIDNEY FUNCTION TESTS; OXIDATIVE STRESS; RATS; RATS, GUNN; RATS, WISTAR; RENAL INSUFFICIENCY;

EID: 84945271702     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep15482     Document Type: Article

References (60)

1. Takamatsu, N. et al. Risk factors for chronic kidney disease in Japan: a community-based study. BMC Nephrol 10, 34 (2009).
2. Yamamoto, R. et al. Association between atherosclerosis and newly classified chronic kidney disease stage for Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 84, 39-45 (2009).
3. Chen, Y. H., Hung, S. C., Tarng, D. C. Serum bilirubin links UGT1A1∗28 polymorphism and predicts long-term cardiovascular events and mortality in chronic hemodialysis patients. Clin J Am Soc Nephrol 6, 567-574 (2011).
4. Fukui, M. et al. Low serum bilirubin concentration in haemodialysis patients with Type 2 diabetes. Diabetic Med 28, 96-99 (2011).
5. Riphagen, I. J. et al. Bilirubin and progression of nephropathy in type 2 diabetes: a post hoc analysis of RENAAL with independent replication in IDNT. Diabetes 63, 2845-2853 (2014).
6. Tanaka, M. et al. Low serum bilirubin concentration is a predictor of chronic kidney disease. Atherosclerosis 234, 421-425 (2014).
7. Oda, E., Aoyagi, R., Aizawa, Y. Hypobilirubinemia might be a possible risk factor of end-stage kidney disease independently of estimated glomerular filtration rate. Kidney Blood Press Res 36, 47-54 (2012).
8. Chin, H. J. et al. The mildly elevated serum bilirubin level is negatively associated with the incidence of end stage renal disease in patients with IgA nephropathy. J Korean Med Sci 24 Suppl, S22-29 (2009).
9. Dvorakova, H. M. et al. Determinants of premature atherosclerosis in children with end-stage renal disease. Physiol Res 61, 53-61 (2012).
10. Boon, A. C., Bulmer, A. C., Coombes, J. S., Fassett, R. G. Circulating bilirubin and defense against kidney disease and cardiovascular mortality: mechanisms contributing to protection in clinical investigations. Am J Physiol Renal Physiol 307, F123-F136 (2014).
11. Wagner, K.-H. et al. Looking to the horizon: the role of bilirubin in the development and prevention of age-related chronic diseases. Clin Sci (Lond) 129, 1-25 (2015).
12. Stocker, R., Peterhans, E. Antioxidant properties of conjugated bilirubin and biliverdin: biologically relevant scavenging of hypochlorous acid. Free Radic Res Commun 6, 57-66 (1989).
13. Neuzil, J., Stocker, R. Free and albumin-bound bilirubin are efficient co-antioxidants for alpha-tocopherol, inhibiting plasma and low density lipoprotein lipid peroxidation. J Biol Chem 269, 16712-16719 (1994).
14. Bulmer, A. C., Blanchfield, J. T., Toth, I., Fassett, R. G., Coornbes, J. S. Improved resistance to serum oxidation in Gilbert's syndrome: A mechanism for cardiovascular protection. Atherosclerosis 199, 390-396 (2008).
15. Fertrin, K. Y., Goncalves, M. S., Saad, S. T., Costa, F. F. Frequencies of UDP-glucuronosyltransferase 1 (UGT1A1) gene promoter polymorphisms among distinct ethnic groups from Brazil. Am J Med Genet 108, 117-119 (2002).
16. Fevery, J. Bilirubin in clinical practice: a review. Liver Int 28, 592-605 (2008).
17. do Sameiro-Faria, M. et al. Potential Cardiovascular Risk Protection of Bilirubin in End-Stage Renal Disease Patients under Hemodialysis. Biomed Res Int 2014, 175286 (2014).
18. Adin, C. A., Croker, B. P., Agarwal, A. Protective effects of exogenous bilirubin on ischemia-reperfusion injury in the isolated, perfused rat kidney. Am J Physiol Renal Physiol 288, F778-784 (2005).
19. Kirkby, K. et al. Intravenous bilirubin provides incomplete protection against renal ischemia-reperfusion injury in vivo. Am J Physiol Renal Physiol 292, F888-894 (2007).
20. Barabas, K. et al. Hyperbilirubinemia's protective effect against cisplatin nephrotoxicity in the Gunn rat. Anticancer Drugs 19, 495-502 (2008).
21. Oh, S. W. et al. Bilirubin attenuates the renal tubular injury by inhibition of oxidative stress and apoptosis. BMC Nephrol 14, 105 (2013).
22. Nasr, S. H. et al. Crystalline nephropathy due to 2,8-dihydroxyadeninuria: an under-recognized cause of irreversible renal failure. Nephrol Dial Transplant 25, 1909-1915 (2010).
23. Zaidan, M. et al. Recurrent 2,8-dihydroxyadenine nephropathy: a rare but preventable cause of renal allograft failure. Am J Transplant 14, 2623-2632 (2014).
24. Terai, K. et al. Vascular calcification and secondary hyperparathyroidism of severe chronic kidney disease and its relation to serum phosphate and calcium levels. Br J Pharmacol 156, 1267-1278 (2009).
25. Okada, H. et al. Reversibility of adenine-induced renal failure in rats. Clin Exp Nephrol 3, 82-88 (1999).
26. Diwan, V., Mistry, A., Gobe, G., Brown, L. Adenine-induced chronic kidney and cardiovascular damage in rats. J Pharmacol Toxicol Methods 68, 197-207 (2013).
27. Tamura, M., Aizawa, R., Hori, M., Ozaki, H. Progressive renal dysfunction and macrophage infiltration in interstitial fibrosis in an adenine-induced tubulointerstitial nephritis mouse model. Histochem Cell Biol 131, 483-490 (2009).
28. Terai, K., Mizukami, K., Okada, M. Comparison of chronic renal failure rats and modification of the preparation protocol as a hyperphosphataemia model. Nephrology (Carlton) 13, 139-146 (2008).
29. Shobeiri, N., Adams, M. A., Holden, R. M. Vascular calcification in animal models of CKD: A review. Am J Nephrol 31, 471-481 (2010).
30. Schrier, R. W. Body Water Homeostasis: Clinical Disorders of Urinary Dilution and Concentration. J Am Soc Nephrol 17, 1820-1832 (2006).
31. Rassam, S. S., Counsell, D. J. Perioperative electrolyte and fluid balance. Continuing Education in Anaesthesia, Critical Care & Pain 5, 157-160 (2005).
32. Poudel, B. et al. Estimation and Comparison of Serum Levels of Sodium, Potassium, Calcium and Phosphorus in Different Stages of Chronic Kidney Disease. Nepal J Epidemiol 1, 160-167 (2011).
33. Kuusniemi, A.-M. et al. Kidneys with heavy proteinuria show fibrosis, inflammation, oxidative stress, but no tubular phenotypic change. Kidney Int 68, 121-132 (2005).
34. Huang, S. S., Huang, P. H., Chiang, K. H., Chen, J. W., Lin, S. J. Association of serum bilirubin levels with albuminuria in patients with essential hypertension. Clin Biochem 44, 859-863 (2011).
35. Shin, H. S., Jung, Y. S., Rim, H. Relationship of serum bilirubin concentration to kidney function and 24-hour urine protein in Korean adults. BMC Nephrol 12, 29 (2011).
36. Kwan, B. C., Kronenberg, F., Beddhu, S., Cheung, A. K. Lipoprotein metabolism and lipid management in chronic kidney disease. J Am Soc Nephrol 18, 1246-1261 (2007).
37. Boon, A. C. et al. Reduced circulating oxidized LDL is associated with hypocholesterolemia and enhanced thiol status in Gilbert syndrome. Free Radic Biol Med 52, 2120-2127 (2012).
38. Wallner, M. et al. Protection from age-related increase in lipid biomarkers and inflammation contributes to cardiovascular protection in Gilbert's syndrome. Clin Sci (Lond) 125, 257-264 (2013).
39. Katsumata, K. et al. Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats. Kidney Int 64, 441-450 (2003).
40. Ikeda, R., Imai, Y., Maruyama, W., Mizoguchi, K. Systemic disorders of calcium dynamics in rats with adenine-induced renal failure: implication for chronic kidney disease-related complications. Nephrology (Carlton) 15, 54-62 (2010).
41. Tanaka, M. et al. Low serum bilirubin concentration is associated with coronary artery calcification (CAC). Atherosclerosis 206, 287-291 (2009).
42. Zhang, Z. Y., Bian, L. Q., Kim, S. J., Zhou, C. C., Choi, Y. H. Inverse relation of total serum bilirubin to coronary artery calcification score detected by multidetector computed tomography in males. Clin Cardiol 35, 301-306 (2012).
43. Hagym?i, K. et al. Further evidence of altered redox status of hyperbilirubinaemic patients: role of bilirubin in Gilbert syndrome. Acta Biol Szeged 47, 131-134 (2003).
44. Oberg, B. P. et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 65, 1009-1016 (2004).
45. Zwoli?ska, D. et al. Oxidative stress in children on peritoneal dialysis. Peritoneal Dialysis International 29, 171-177 (2009).
46. Boon, A. C., Hawkins, C. L., Coombes, J. S., Wagner, K. H., Bulmer, A. C. Bilirubin scavenges chloramines and inhibits myeloperoxidase-induced protein/lipid oxidation in physiologically relevant hyperbilirubinemic serum. Free Radic Biol Med 86, 259-268 (2015).
47. Hawkins, C. L., Pattison, D. I., Davies, M. J. Hypochlorite-induced oxidation of amino acids, peptides and proteins. Amino Acids 25, 259-274 (2003).
48. Matsuyama, Y., Terawaki, H., Terada, T., Era, S. Albumin thiol oxidation and serum protein carbonyl formation are progressively enhanced with advancing stages of chronic kidney disease. Clin Exp Nephrol 13, 308-315 (2009).
49. Capeille-Blandin, C. et al. Respective role of uraemic toxins and myeloperoxidase in the uraemic state. Nephrol Dial Transplant 21, 1555-1563 (2006).
50. Caimi, G., Carollo, C., Hopps, E., Montana, M., Lo Presti, R. Protein oxidation in chronic kidney disease. Clin Hemorheol Microcirc 54, 409-413 (2013).
51. Tucker, P. S., Dalbo, V. J., Han, T., Kingsley, M. I. Clinical and research markers of oxidative stress in chronic kidney disease. Biomarkers 18, 103-115 (2013).
52. Frei, B., Stocker, R., Ames, B. N. Antioxidant defenses and lipid peroxidation in human blood plasma. Proc Natl Acad Sci USA 85, 9748-9752 (1988).
53. Dennery, P. A., Mcdonagh, A. F., Spitz, D. R., Rodgers, P. A., Stevenson, D. K. Hyperbilirubinemia Results in Reduced Oxidative Injury in Neonatal Gunn-Rats Exposed to Hyperoxia. Free Radic Bio Med 19, 395-404 (1995).
54. Liu, Y. Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol 7, 684-696 (2011).
55. Poulsen, H. E., Nadal, L. L., Broedbaek, K., Nielsen, P. E., Weimann, A. Detection and interpretation of 8-oxodG and 8-oxoGua in urine, plasma and cerebrospinal fluid. Biochim Biophys Acta 1840, 801-808 (2014).
56. Bulmer, A. C. et al. Bile pigment pharmacokinetics and absorption in the rat: therapeutic potential for enteral administration. Brit J Pharmacol 164, 1857-1870 (2011).
57. Hissin, P. J., Hilf, R. A fluorometric method for determination of oxidized and reduced glutathione in tissues. Anal Biochem 74, 214-226 (1976).
58. Hawkins, C. L., Morgan, P. E., Davies, M. J. Quantification of protein modification by oxidants. Free Radic Biol Med 46, 965-988 (2009).
59. Briskey, D. R., Wilson, G. R., Fassett, R. G., Coombes, J. S. Optimized method for quantification of total F(2)-isoprostanes using gas chromatography-tandem mass spectrometry. J Pharm Biomed Anal 90, 161-166 (2014).
60. Lee, K. F., Chung, W. Y., Benzie, I. F. Urine 8-oxo-7,8-dihydro-2-deoxyguanosine (8-oxodG), a specific marker of oxidative stress, using direct, isocratic LC-MS/MS: Method evaluation and application in study of biological variation in healthy adults. Clin Chim Acta 411, 416-422 (2010).